Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer.

IF 3.1 2区医学 Q2 ONCOLOGY Journal of Cancer Survivorship Pub Date : 2024-10-01 Epub Date: 2023-06-01 DOI:10.1007/s11764-023-01408-y

Anna-Carson Rimer Uhelski, Amanda L Blackford, Jennifer Y Sheng, Claire Snyder, Jennifer Lehman, Kala Visvanathan, David Lim, Vered Stearns, Karen Lisa Smith

{"title":"Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer.","authors":"Anna-Carson Rimer Uhelski, Amanda L Blackford, Jennifer Y Sheng, Claire Snyder, Jennifer Lehman, Kala Visvanathan, David Lim, Vered Stearns, Karen Lisa Smith","doi":"10.1007/s11764-023-01408-y","DOIUrl":null,"url":null,"abstract":"Purpose: Weight gain after breast cancer poses health risks. We aimed to identify factors associated with weight gain during adjuvant endocrine therapy (AET).Methods: Women initiating AET enrolled in a prospective cohort. Participants completed FACT-ES plus PROMIS pain interference, depression, anxiety, fatigue, sleep disturbance and physical function measures at baseline, 3, 6, 12, 24, 36, 48 and 60 months. Treatment-emergent symptoms were defined as changes in scores in the direction indicative of worsening symptoms that exceeded the minimal important difference at 3 and/or 6 months compared to baseline. We used logistic regression to evaluate associations of clinicodemographic features and treatment-emergent symptoms with clinically significant weight gain over 60 months (defined as ≥ 5% compared to baseline) in pre- and post-menopausal participants.Results: Of 309 participants, 99 (32%) were pre-menopausal. The 60 months cumulative incidence of clinically significant weight gain was greater in pre- than post-menopausal participants (67% vs 43%, p < 0.001). Among pre-menopausal participants, treatment-emergent pain interference (OR 2.49), aromatase inhibitor receipt (OR 2.8), mastectomy, (OR 2.06) and White race (OR 7.13) were associated with weight gain. Among post-menopausal participants, treatment-emergent endocrine symptoms (OR 2.86), higher stage (OR 2.25) and White race (OR 2.29) were associated with weight gain while treatment-emergent physical function decline (OR 0.30) was associated with lower likelihood of weight gain.Conclusions: Weight gain during AET is common, especially for pre-menopausal women. Clinicodemographic features and early treatment-emergent symptoms may identify at risk individuals.Implications for cancer survivors: Patients at risk for weight gain can be identified early during AET.Clinical trials: Gov identifier: NCT01937052, registered September 3, 2013.","PeriodicalId":15284,"journal":{"name":"Journal of Cancer Survivorship","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424737/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Survivorship","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11764-023-01408-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Weight gain after breast cancer poses health risks. We aimed to identify factors associated with weight gain during adjuvant endocrine therapy (AET).

Methods: Women initiating AET enrolled in a prospective cohort. Participants completed FACT-ES plus PROMIS pain interference, depression, anxiety, fatigue, sleep disturbance and physical function measures at baseline, 3, 6, 12, 24, 36, 48 and 60 months. Treatment-emergent symptoms were defined as changes in scores in the direction indicative of worsening symptoms that exceeded the minimal important difference at 3 and/or 6 months compared to baseline. We used logistic regression to evaluate associations of clinicodemographic features and treatment-emergent symptoms with clinically significant weight gain over 60 months (defined as ≥ 5% compared to baseline) in pre- and post-menopausal participants.

Results: Of 309 participants, 99 (32%) were pre-menopausal. The 60 months cumulative incidence of clinically significant weight gain was greater in pre- than post-menopausal participants (67% vs 43%, p < 0.001). Among pre-menopausal participants, treatment-emergent pain interference (OR 2.49), aromatase inhibitor receipt (OR 2.8), mastectomy, (OR 2.06) and White race (OR 7.13) were associated with weight gain. Among post-menopausal participants, treatment-emergent endocrine symptoms (OR 2.86), higher stage (OR 2.25) and White race (OR 2.29) were associated with weight gain while treatment-emergent physical function decline (OR 0.30) was associated with lower likelihood of weight gain.

Conclusions: Weight gain during AET is common, especially for pre-menopausal women. Clinicodemographic features and early treatment-emergent symptoms may identify at risk individuals.

Implications for cancer survivors: Patients at risk for weight gain can be identified early during AET.

Clinical trials:

Gov identifier: NCT01937052, registered September 3, 2013.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受乳腺癌辅助内分泌治疗的绝经前后妇女体重增加的相关因素。

目的：乳腺癌术后体重增加会带来健康风险。我们旨在确定辅助内分泌治疗（AET）期间体重增加的相关因素：方法：开始接受辅助内分泌治疗的妇女参加了一项前瞻性队列研究。参与者分别在基线、3、6、12、24、36、48 和 60 个月完成 FACT-ES 和 PROMIS 疼痛干扰、抑郁、焦虑、疲劳、睡眠障碍和身体功能测量。治疗突发症状的定义是，与基线相比，3 个月和/或 6 个月时症状恶化方向上的评分变化超过最小重要差异。我们使用逻辑回归法评估了绝经前和绝经后参与者的临床人口学特征和治疗突发症状与60个月内临床显著体重增加（定义为与基线相比体重增加≥5%）的相关性：在 309 名参与者中，99 人（32%）绝经前。绝经前和绝经后参与者在 60 个月内体重明显增加的累积发生率更高（67% 对 43%，P 结论：绝经前和绝经后参与者在 60 个月内体重增加的累积发生率更高（67% 对 43%，P）：AET 期间体重增加很常见，尤其是绝经前妇女。临床人口学特征和早期治疗突发症状可识别高危人群：临床试验：Gov identifier：临床试验：Gov标识符：NCT01937052，2013年9月3日注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cancer Survivorship ONCOLOGY-

CiteScore

7.00

自引率

10.80%

发文量

149

审稿时长

>12 weeks

期刊介绍： Cancer survivorship is a worldwide concern. The aim of this multidisciplinary journal is to provide a global forum for new knowledge related to cancer survivorship. The journal publishes peer-reviewed papers relevant to improving the understanding, prevention, and management of the multiple areas related to cancer survivorship that can affect quality of care, access to care, longevity, and quality of life. It is a forum for research on humans (both laboratory and clinical), clinical studies, systematic and meta-analytic literature reviews, policy studies, and in rare situations case studies as long as they provide a new observation that should be followed up on to improve outcomes related to cancer survivors. Published articles represent a broad range of fields including oncology, primary care, physical medicine and rehabilitation, many other medical and nursing specialties, nursing, health services research, physical and occupational therapy, public health, behavioral medicine, psychology, social work, evidence-based policy, health economics, biobehavioral mechanisms, and qualitative analyses. The journal focuses exclusively on adult cancer survivors, young adult cancer survivors, and childhood cancer survivors who are young adults. Submissions must target those diagnosed with and treated for cancer.